BDBM176184 US10047103, 258::US9688695, 217::US9688695, 258

SMILES COc1cc(OCc2csc(n2)N2CCSCC2)c2cc(oc2c1)-c1cn2nc(C)ccc2n1

InChI Key InChIKey=NDKCBLNZBSRGIG-UHFFFAOYSA-N

Data  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 176184   

TargetProteinase-activated receptor 4(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176184(US9688695, 217 | US10047103, 258 | US9688695, 258)
Affinity DataEC50:  0.610nMT: 2°CAssay Description:Briefly, HEK293 EBNA PAR4 clone 20664.1J cells were plated 24 hrs. prior to experiment in 384 well, Poly-D-Lysine coated, black, clear bottom plates ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
US Patent

TargetProteinase-activated receptor 4(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176184(US9688695, 217 | US10047103, 258 | US9688695, 258)
Affinity DataEC50:  0.610nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
US Patent

TargetProteinase-activated receptor 4(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176184(US9688695, 217 | US10047103, 258 | US9688695, 258)
Affinity DataEC50:  0.810nMT: 2°CAssay Description:Briefly, HEK293 EBNA PAR4 clone 20664.1J cells were plated 24 hrs. prior to experiment in 384 well, Poly-D-Lysine coated, black, clear bottom plates ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2018
Entry Details
US Patent

TargetProteinase-activated receptor 4(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176184(US9688695, 217 | US10047103, 258 | US9688695, 258)
Affinity DataEC50:  0.810nMT: 2°CAssay Description:The activity of the PAR4 antagonists of the present invention were tested in PAR4 expressing cells by monitoring H-Ala-Phe(4-F)-Pro-Gly-Trp-Leu-Val-L...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2018
Entry Details
US Patent